New research suggests that a high fat diet could reduce the bacteria of the gut and, therefore, fight against the harmful inflammation that Crohn’s disease patients experience.
New research suggests that a high fat diet could reduce the bacteria of the gut and, therefore, fight against the harmful inflammation that Crohn’s disease patients experience.
In Case Western Reserve University School of Medicine’s study, the researchers observed a significant decrease in bacterial diversity in mice with Crohn’s-like disease when they were on a plant diet with “good” fats like coconut oil and cocoa butter. The study found that mice on the “good” fat diet had up to 30% fewer types of bacteria in the gut when compared to those fed their normal diet.
There was an apparent different microbial composition between those with the beneficial fat diet and those without. Some of the changes in the mice were found in the feces, while others were apparent in the cecum. Regardless of observation location, the study witnessed a decrease of severe intestine inflammation in mice fed even only low concentrations of coconut oil and cocoa butter.
“The finding is remarkable because it means that a Crohn’s patient could also have a beneficial effect on their gut bacteria and inflammation by only switching the type of fat in their diet,” Alexander Rodriguez-Palacios, DVM, DVSc, PhD, the first author on the study and assistant professor of Medicine at Case Western Reserve University, said in a statement. “Patients would only need to replace a ‘bad’ fat with a ‘good’ fat, and eat normal amounts.”
Since this study is one of the first to indicate an association between changes in gut bacteria and Crohn’s disease, more studies are necessary to fully understand the influence of a “good” fat diet on fighting Crohn’s disease. Even so, results from this study could assist doctors in treating their patients with Crohn’s disease and help them identify the bacteria to use in a probiotic.
“Not all ‘good’ fats might be good in all patients,” warned Rodriguez-Palacios. “Mice indicate that each person could respond differently. But diet is something we are very hopeful could help at least some patients without the side-effects and risks carried by drugs. The trick now is to really discover what makes a fat ‘good’ or ‘bad’ for Crohn’s disease.”
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More